BayVax Biotech leverages proprietary deep learning frameworks to simulate complex immune interactions, enabling the rapid design and validation of novel antigens for next-generation personalised and broad-spectrum vaccines.
Our computational platform models molecular interactions involved in immune recognition, supporting neoantigen selection and therapeutic design.
Fusion-pM and Fusion-pMT model peptide–HLA binding and TCR recognition to support neoantigen prioritisation.
View WebserverEnables de novo design of T-cell receptor (TCR) sequences engineered for high-affinity binding.
An integrated suite for the entire computational workflow, from in-silico HLA genotyping to generative design.
We are translating computational insights into a new generation of tangible therapeutic strategies for oncology and infectious diseases.
Deploying our validated computational pipelines through strategic licensing and co-development partnerships.
Developing patient-specific neoantigen vaccines for solid tumors, demonstrating significant PFS extension.
Designing novel antigens that elicit broad-spectrum, cross-reactive immune responses to diverse pathogens.
Peptide binding to HLA precedes recognition by a T-cell receptor. Our sequence-fusion models follow this biological order to help prioritise patient-specific neoantigen candidates.
Can the peptide bind to the patient's HLA?
Cross-attention learns interactions between peptide and HLA residues. Padding-aware positional encoding and masking preserve sequence information across different peptide lengths.
Output: peptide–HLA binding probability (0–1)
Can a specific TCR recognise the pMHC?
Shared amino-acid encoding and sequential cross-attention fuse all three sequences. Peptide–MHC pretraining supports subsequent fine-tuning on peptide–MHC–TCR binding data.
Output: TCR-specific triad binding score
Without TCR data, candidates can be prioritised using peptide–HLA binding and expression. Binding is one component of antigen presentation; these scores support selection and do not by themselves establish T-cell activation or clinical efficacy.
515,149 training pairs; 82,112 held-out test pairs. ROC-AUC ≥0.90 across all 112 evaluated HLA alleles.
| Test set | ROC-AUC | ACC |
|---|---|---|
| Unseen peptide | 0.7326 | 0.7092 |
| Out of distribution | 0.6320 | 0.6001 |
Computational evidence and clinical trial outcomes address different questions. BXP-001 clinical research is presented in Events.
Available .
Our research is advancing through preclinical and clinical stages, validating the power of our AI-driven approach.
| Candidates | Vaccines | Modality | In-Silico | Preclinical | Clinical |
|---|---|---|---|---|---|
| BXP-001 | Neoantigen Cancer Vaccine | Peptide | IIT | ||
| BVX-COV | Pan-Coronavirus Vaccine | Viral Vector | |||
| BVX-AGE | Senolytic (Anti-Aging) Vaccine | Protein | |||
| BVX-AID | Autoimmune Disease Vaccine | Peptide |
Updated results of the randomised phase II iNATURE trial have been accepted for ESMO Congress 2026 (LBA52 and 2005P). View event & posters →
The regulatory pathway is opened for neoantigen vaccines, paving the way for our Investigational New Drug application.
The randomised IIT (iNATURE) at HKU-Shenzhen Hospital has started.
An investigator-initiated trial Individualized Neoantigen Therapy With Unusual Radiotherapy Enhancement (iNATURE) at The University of Hong Kong-Shenzhen Hospital has been approved by Institutional Review Board.
Previous Investigator-Initiated Trials in solid tumours (HCC, MSS-CRC) showed significantly extended Progression-Free Survival (PFS).
– · Madrid, Spain
Two results from the randomised phase II iNATURE study (GCOG0028) examine personalised neoantigen vaccination with critical lesion radiotherapy (CLERT), including interim efficacy and the relationship between radiation exposure and immune preservation.
Prespecified interim analysis of the randomised phase II trial: progression-free survival, immune responses and safety.
Available .
Exploratory interim analysis of radiation exposure to immune cells, lymphocyte nadir and clinical outcomes.
Available .
–
Barcelona, Spain
WCLC 2025 · Poster P2.10.14
Individualized Neoantigen Therapy With Unusual Radiotherapy Enhancement (iNATURE): a Phase II Randomized Study.
Explore our peer-reviewed articles, research preprints and congress presentations.
‡ First author(s) | * Correspondence author(s)
Transparent records of our procurement and vendor partnerships.
| Project Title | Preclinical Toxicity Study for Peptide-Based Neoantigen Cancer Vaccine |
| Reference No | TOX-2025-001 |
| Budget | Not exceeding HKD 1,500,000 |
| Deadline | June 6, 2025 |
The tender announcement was officially released on May 14, 2025. By the deadline of June 6, 2025, bid documents from three qualified vendors were received and shortlisted for in-depth evaluation. As of June 13, 2025 the results of this tender has been released.
Pharmaron Beijing Co., Ltd. is recommended as the preferred partner for this project.
| Rank | Vendors | Score |
|---|---|---|
| 1 | Pharmaron Beijing Co., Ltd. 康龙化成（北京）新药技术股份有限公司 |
93.67 |
| 2 | Vendor 2 | 87.67 |
| 3 | Vendor 3 | 74.33 |
Public notice period: June 13, 2025 - June 17, 2025.
If a bidder or any other interested party has an objection to the bid evaluation results, they must submit a written objection to the tendering entity during the public notice period. The tendering entity will provide a written response within three (3) days of receiving the objection. Bidding activities will be suspended until a response is issued.
If the bidder or interested party remains dissatisfied with the tendering entity’s response, they may file a formal complaint with the relevant industry regulatory authority or public resource trading supervision agency within ten (10) days of receiving the response. The complaint must include the tendering entity’s reply and a written complaint letter.
| Project Title | Preclinical Toxicity Study for Peptide-Based Neoantigen Cancer Vaccine |
| Reference No | TOX-2025-001 |
| Budget | Not exceeding HKD 1,500,000 |
| Deadline | June 6, 2025 |
We seek qualified Contract Research Organizations (CROs) to conduct an IND-enabling toxicity study for a peptide-based neoantigen cancer vaccine. This study is critical to support Investigational New Drug (IND) applications to the Center for Drug Evaluation (CDE) in China and the U.S. Food and Drug Administration (FDA).
| Citerion | Weight |
|---|---|
| Scientific & Technical Merit | 40% |
| Regulatory Compliance | 30% |
| Cost-Effectiveness | 20% |
| Past Performance | 10% |
Note: Proposals exceeding the budget cap will be disqualified. Inquiries must be submitted by June 10, 2025.
Uniting with pioneering partners to accelerate breakthrough therapies.
Discover our vision for AI-powered immune programming and the future of personalized medicine.